Daraxonrasib is going up against standard-of-care chemotherapy, in the second line for metastatic pancreatic cancer (and its being tested as first-line therapy, and in resectable disease, alongside this)
The brain was never supposed to be a dead end
Clinicians can increase their chances of success by: Submitting a clear, one-page letter of medical necessity that outlines FDA approval and the patients eligibility Documenting comorbid conditions, prior therapies and BMI trends Utilizing well-organized templates Engaging dedicated staff for navigating the prior authorization process Despite these efforts, barriers remain
reports honoraria and/or consulting fees from Abbott, AstraZeneca, Medtronic, Novo Nordisk, Occlutech, Pharmacosmos and Vifor
"Glutamine and glutamate as vital metabolites"
They have been shamed often, Moravec said